Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients

Liver International

Volumn 31, Issue 5, 2011, Pages 730-739

  Manousou, Pinelopi ^a   Kalambokis, George ^a   Grillo, Federica ^b   Watkins, Jennifer ^b   Xirouchakis, Elias ^a   Pleguezuelo, Maria ^a   Leandro, Gioacchino ^a   Arvaniti, Vasiliki ^a   Germani, Giacomo ^a   Patch, David ^a   Calvaruso, Vincenza ^a   Mikhailidis, Dimitri P ^b   Dhillon, Amar P ^b   Burroughs, Andrew K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Ferritin; Fibrosis; Inflammation; NAFLD; NASH

Indexed keywords

BIOLOGICAL MARKER; FERRITIN;

ADULT; AGED; ARTICLE; BODY MASS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FERRITIN BLOOD LEVEL; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL ANALYSIS;

ADULT; AGED; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; DIABETES COMPLICATIONS; FATTY LIVER; FEMALE; FERRITINS; HEPATITIS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIVER CIRRHOSIS; LOGISTIC MODELS; LONDON; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NOMOGRAMS; OBESITY; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 79953322846     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02488.x     Document Type: Article

References (55)

1. Lonardo A, Bellini M, Tartoni P, et al. The bright liver syndrome prevalence and determinants of a 'bright' liver echopattern. Ital J Gastroenterol Hepatol 1997; 29: 351-6.
2. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001; 35: 195-9.
3. Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-5.
4. Brunt EM. Nonalcoholic steatohepatitis: definition and Pathology. Semin Liver Dis 2001; 21: 3-16.
5. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
6. Ludwig J, McGill DB, Lindor KD. Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol 1997; 12: 398-403.
7. Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
8. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
9. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
10. Garcia-Monzon C, Martin-Perez E, Iacono OL, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000; 33: 716-24.
11. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485-93.
12. Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res 2005; 33: 68-71.
13. Bedogni G, Miglioli L, Masutti F, et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007; 46: 1387-91.
14. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-9.
15. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a who consultation. Diabet Med 1998; 15: 539-53.
16. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.
17. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
18. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
19. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
20. Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987; 82: 650-4.
21. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
22. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
23. Bell H, Skinningsrud A, Raknerud N, et al. Serum ferritin and transferrin saturation in patients with chronic alcoholic and non-alcoholic liver diseases. J Intern Med 1994; 236: 315-22.
24. Fargion S, Mattioli M, Fracanzani AL, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 2448-55.
25. Turnbull AJ, Mitchison HC, Peaston RT, et al. The prevalence of hereditary haemochromatosis in a diabetic population. QJM 1997; 90: 271-5.
26. Turlin B, Mendler MH, Moirand R, et al. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol 2001; 116: 263-70.
27. Fernandez-Real JM, Ricart-Engel W, Arroyo E, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998; 21: 62-8.
28. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE Gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421-9.
29. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-8.
30. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998; 29: 495-501.
31. Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-9.
32. Sibille JC, Kondo H, Aisen P. Interactions between isolated hepatocytes and kupffer cells in Iron metabolism: a possible role for ferritin as an iron carrier protein. Hepatology 1988; 8: 296-301.
33. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, et al. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol 2007; 46: 700-7.
34. Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord 2004; 28: 167-72.
35. Yajima Y, Takahashi N, Miyazaki A, et al. Prevalence of non-alcoholic steatohepatitis (NASH) among biopsied cases of a urban hospital in Japan: significance of measurement of serum ferritin in the detection of NASH. Nippon Shokakibyo Gakkai Zasshi 2006; 103: 515-22.
36. Bugianesi E, Marchesini G, Gentilcore E, et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 2006; 44: 1648-55.
37. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39: 179-87.
38. de Ledinghen V, Combes M, Trouette H, et al. Should a liver biopsy be done in patients with subclinical chronically elevated transaminases? Eur J Gastroenterol Hepatol 2004; 16: 879-83.
39. Giostra E, Huber O, Morel P, et al. Liver disease in obese patients. Rev Med Suisse 2007; 3: 1939-41.
40. Loguercio C, De Simone T, D'Auria MV, et al. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the study of the liver. Dig Liver Dis 2004; 36: 398-405.
41. Moon JH, Park SH, Oh KC, et al. Association of hepatic iron deposition and serum iron indices with hepatic inflammation and fibrosis stage in nonalcoholic fatty liver disease. Korean J Gastroenterol 2006; 47: 432-9.
42. Canbakan B, Senturk H, Tahan V, et al. Clinical, biochemical and histological correlations in a group of non-drinker subjects with non-alcoholic fatty liver disease. Acta Gastroenterol Belg 2007; 70: 277-84.
43. Shimada M, Hashimoto E, Kaneda H, et al. Nonalcoholic steatohepatitis: risk factors for liver fibrosis. Hepatol Res 2002; 24: 429-38.
44. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
45. Koruk M, Taysi S, Savas MC, et al. Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis. Turk J Gastroenterol 2003; 14: 12-7.
46. Albano E, Mottaran E, Vidali M, et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 2005; 54: 987-93.
47. Fierbinteanu-Braticevici C, Bengus A, Neamtu M, et al. The risk factors of fibrosis in nonalcoholic steatohepatitis. Rom J Intern Med 2002; 40: 81-8.
48. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum lanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
49. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
50. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
51. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006; 101: 2629-40.
52. Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132-8.
53. Chavez-Tapia NC, Tiribelli C. Are non-invasive tests accurate enough to predict hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD)? Gut 2008; 57: 1351-3.
54. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-7.
55. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792-8.